中文 | English
Return
Total: 27 , 1/3
Show Home Prev Next End page: GO
MeSH:(Pyrimidines/*adverse effects/therapeutic use)

2.Reversible Dysphasia and Statins.

Gordon Robert Wyndham DAVIES

Journal of Korean Medical Science 2012;27(4):458-459

3.Clinical efficacy of rosuvastatin in lipid management in Chinese patients in Hong Kong.

Vivian W Y LEE ; T S CHAU ; Vice P H LEUNG ; Kenneth K C LEE ; Brian TOMLINSON

Chinese Medical Journal 2009;122(23):2814-2819

5.Diagnosis and treatment of fungal infection after liver transplantation.

Xian-Jie SHI ; Shao-Cheng LÜ ; Lei HE ; Fang LU ; Yu-Rong LIANG ; Ying LUO ; Wen-Bin JI ; Zhi-Ming ZHAO

Chinese Medical Journal 2011;124(7):1015-1017

6.The efficacy and safety of rosuvastatin on treating patients with hypercholesterolemia in Chinese: a randomized, double-blind, multi-center clinical trial.

Run-lin GAO

Chinese Journal of Cardiology 2007;35(3):207-211

7.The Clinical Observation with Ruxolitinib as Graft-Versus-Host Disease Prophylaxis for Children with Thalassemia after Unrelated or Haploidentical Allo-Hematopoietic Stem Cell Transplantation.

Ya-Mei CHEN ; Xiu-Li HONG ; Jin-Zong LIN ; Jie SHI ; Quan-Yi LU

Journal of Experimental Hematology 2022;30(5):1586-1589

8.Treatment of 54 chronic myelogenous leukemia with Gleevec.

Hao JIANG ; Shan-shan CHEN ; Bin JIANG ; Qian JIANG ; Dao-pei LU

Chinese Journal of Hematology 2003;24(6):281-285

9.Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia.

Li ZHOU ; Jian-xiang WANG ; Xiao-jun HUANG ; Jian-da HU ; Zhi-xiang SHEN

Chinese Journal of Hematology 2013;34(2):93-97

10.Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.

Zhan-Guo LI ; Yi LIU ; Hu-Ji XU ; Zhi-Wei CHEN ; Chun-De BAO ; Jie-Ruo GU ; Dong-Bao ZHAO ; Yuan AN ; Lie-Ju HWANG ; Lisy WANG ; Joel KREMER ; Qi-Zhe WU

Chinese Medical Journal 2018;131(22):2683-2692

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 27 , 1/3 Show Home Prev Next End page: GO